# Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia

> **NCT03988205** · PHASE4 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 3 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BEHAVIORAL:** Outpatient Care Model
- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT03988205
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-28
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988205, "Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03988205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*